Kane Biotech Valuation
| KNE Stock | CAD 0.04 0.00 0.00% |
Kane Biotech seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Kane Biotech from analyzing the firm fundamentals such as Operating Margin of (63.94) %, return on equity of -5.97, and Shares Outstanding of 167.35 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Kane Biotech's valuation include:
Price Book 104.3821 | Enterprise Value | Enterprise Value Ebitda (6.17) | Price Sales 11.6442 | Enterprise Value Revenue 14.007 |
Overvalued
Today
Please note that Kane Biotech's price fluctuation is out of control at this time. Calculation of the real value of Kane Biotech is based on 3 months time horizon. Increasing Kane Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Kane stock is determined by what a typical buyer is willing to pay for full or partial control of Kane Biotech. Since Kane Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kane Stock. However, Kane Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.04 | Real 0.0375 | Hype 0.03 |
The intrinsic value of Kane Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kane Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kane Biotech helps investors to forecast how Kane stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kane Biotech more accurately as focusing exclusively on Kane Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Kane Biotech's intrinsic value based on its ongoing forecasts of Kane Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Kane Biotech's closest peers.
Kane Biotech Cash |
|
About Kane Biotech Valuation
Our relative valuation model uses a comparative analysis of Kane Biotech. We calculate exposure to Kane Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kane Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1 M | 1.1 M | |
| Pretax Profit Margin | (1.93) | (2.03) | |
| Operating Profit Margin | (1.94) | (2.04) | |
| Net Loss | (1.31) | (1.37) | |
| Gross Profit Margin | 0.38 | 0.36 |
Additional Tools for Kane Stock Analysis
When running Kane Biotech's price analysis, check to measure Kane Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kane Biotech is operating at the current time. Most of Kane Biotech's value examination focuses on studying past and present price action to predict the probability of Kane Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kane Biotech's price. Additionally, you may evaluate how the addition of Kane Biotech to your portfolios can decrease your overall portfolio volatility.